Scleredema diabeticorum partially treated with low-dose methotrexate : A report of five cases
Loading...
Date
2012
Journal Title
Journal ISSN
Volume Title
Publisher
Access Rights
info:eu-repo/semantics/openAccess
Abstract
Skleredema nadir görülen skleroderma-benzeri bir grup konnektif doku hastalıklarından biridir. Bilinen küratif bir tedavisi olmamakla birlikte literatürde birçok tedavi şekli bildirilmiştir. Burada düşük-doz metotreksate tedavisine kısmen cevap veren 5 olgu sunulmaktadır. Tüm hastalar aynı zamanda tip II diyabetes mellitus hastası idi. Tüm hastalara 3 ay süre ile subkutan yolla 15mg/hafta metotreksate tedavisi verildi. Tüm hastalaradan tedavi öncesi ve tedavi sonrası biyopsi alınarak karşılaştırıldı. Tüm hastaların bu tedaviye kısmen cevap verdiği histopatolojik olarak gösterildi. Sonuç olarak, düşük doz metotreksate tedavisi skleredema için alternatif bir tedavi metodu olabilir.
Scleredema is a rare connective tissue disorder that belongs to a group of scleroderma-like disorders. Although no known curative therapy exists, various specific treatments have been proposed in the literature. In this report, we describe five cases of scleredema partially treated with low-dose methotrexate therapy. All patients have diabetes mellitus type II. All patients were started on methotrexate 15 mg subcutaneously once weekly for 3 months. Biopsy specimens were taken from all patients and were examinated histologically before the treatment and after 3 months of treatment. All cases partially responded to low-dose methotrexate therapy. We believe that methotrexate therapy may be an alternative therapeutic options in scleredema in view of its efficacy.
Scleredema is a rare connective tissue disorder that belongs to a group of scleroderma-like disorders. Although no known curative therapy exists, various specific treatments have been proposed in the literature. In this report, we describe five cases of scleredema partially treated with low-dose methotrexate therapy. All patients have diabetes mellitus type II. All patients were started on methotrexate 15 mg subcutaneously once weekly for 3 months. Biopsy specimens were taken from all patients and were examinated histologically before the treatment and after 3 months of treatment. All cases partially responded to low-dose methotrexate therapy. We believe that methotrexate therapy may be an alternative therapeutic options in scleredema in view of its efficacy.
Description
Keywords
Cerrahi
Journal or Series
Balkan Medical Journal
WoS Q Value
Scopus Q Value
Volume
29
Issue
2